Woodline Partners LP Supernus Pharmaceuticals, Inc. Call Options Transaction History
Woodline Partners LP
- $11 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SUPN
# of Institutions
281Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$368 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$217 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$181 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$102 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$93.2 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.9B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...